High persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort study
{{output}}
Objectives: The number of advanced therapies for inflammatory bowel disease (IBD) has increased in recent years. Ustekinumab, an inhibitor of interleukin -12 and -23, was mostly used for later-line treatment, where its efficacy m... ...
